Copilot: Anavex Life Sciences is set to begin a Phase II clinical trial for ANAVEX 3-71, a drug candidate aimed at treating schizophrenia. The trial has received FDA clearance and is expected to start in the second quarter of 2024. ANAVEX 3-71, which was previously known as AF710B, is a dual sigma non-opioid intracellular receptor 1 (SIGMAR1) receptor agonist and M1 positive allosteric modulator. The study will be placebo-controlled and will initially analyze various ascending doses of the drug in schizophrenia patients, followed by a 28-day treatment period in a larger cohort. The trial will include standard clinical outcome measures for schizophrenia, such as the Positive and Negative Symptoms Scale (PANSS), and new electrophysiological biomarkers. The unique mechanism of action of ANAVEX 3-71 is believed to offer a comprehensive treatment option for all symptom domains of schizophrenia, potentially alleviating the side effects associated with standard antipsychotic medications1.
7 Likes
Exciting stuff!
3 Likes